NCT06489249

Role of Inflammation in Vascular Phenotype Associated With E-cigarette Use

• Status: Recruiting
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 24 (estimated)
• Sponsor: University of Iowa · Academic / Other
• Sex: All
• Age: 18 Years – 24 Years
• Healthy volunteers: Accepted

Summary

The use of electronic nicotine delivery systems, or e-cigarettes - colloquially referred to as "vaping" - in the United States has increased exponentially since their introduction to the US market in 2007. Prevalence of ever and current e-cigarette use is highest among teenagers and young adults with 16-28% of this population having reported vaping. While the majority of e-cigarette users are current tobacco smokers, 32.5% of current e-cigarette users are never- or former-smokers, representing a growing population of young adults who exclusively vape. While e-cigarettes have been marketed as a safer alternative to tobacco cigarettes, clinical studies examining these claims are limited. Cardiovascular disease (CVD) is the primary cause of premature death among tobacco cigarette smokers and reductions in vascular endothelial function, a significant predictor of future CVD, are detectible in otherwise healthy young adults who smoke. Despite the explosion in e-cigarette use among young adults, the health effects - especially the effects on mechanisms of vascular function - of these devices remain relatively unexplored. The purpose of this study is to directly asses the mechanistic role of inflammation in this dysfunction.

Conditions

• Electronic Cigarette Use
• Endothelial Dysfunction
• Inflammation

Interventions

Type	Name	Description
DRUG	Placebo	Oral placebo tablet
DRUG	Salsalate 750 MG Oral Tablet [DISALCID]	Oral salsalate tablet

Timeline

• Start date: 2024-08-15
• Primary completion: 2026-06-01
• Completion: 2026-10-01
• First posted: 2024-07-05
• Last updated: 2025-12-15

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study